Dr Richard G. Gray presents data during a press conference at the 2013 ASCO Annual Meeting on the British aTTom study.

The study found ten years of adjuvant treatment with tamoxifen provided women with oestrogen-receptor-positive (ER ) breast cancer greater protection against late recurrence and death than the current standard of only five years of tamoxifen. While side effects are also increased with longer tamoxifen use, the researchers conclude that the overall benefits greatly outweigh the risk of continuing therapy. The findings from aTTom, a Phase III randomized study, complement and confirm the results of the recently published international study, ATLAS.

Visit ecancerNews to read more